Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

Immunovant, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW YORK, JULY 20, 2026 (GLOBE NEWSWIRE) -- KUEHN LAW, PLLC, A SHAREHOLDER LITIGATION LAW FIRM, IS INVESTIGATING WHETHER CERTAIN OFFICERS AND DIRECTORS OF IMMUNOVANT, INC. (NASDAQ: IMVT) BREACHED THEIR FIDUCIARY DUTIES TO SHAREHOLDERS. THE INVESTIGATION CONCERNS POTENTIAL SELF-DEALING. SHAREHOLDERS MAY BE ENTITLED TO DAMAGES AND CORPORATE GOVERNANCE REFORMS.

KUEHN LAW ENCOURAGES INVESTORS OF IMMUNOVANT, INC. TO CONTACT LAW FIRM

DURHAM, N.C., MAY 20, 2026 (GLOBE NEWSWIRE) -- IMMUNOVANT, INC. (NASDAQ: IMVT), A CLINICAL-STAGE IMMUNOLOGY COMPANY DEDICATED TO ENABLING NORMAL LIVES FOR PEOPLE WITH AUTOIMMUNE DISEASES, TODAY REPORTED CORPORATE UPDATES AND FINANCIAL RESULTS FOR ITS FOURTH QUARTER AND FISCAL YEAR ENDED MARCH31, 2026.

IMMUNOVANT PROVIDES CORPORATE UPDATES AND REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FISCAL YEAR ENDED MARCH 31, 2026

DURHAM, N.C., MAY 11, 2026 (GLOBE NEWSWIRE) -- IMMUNOVANT (NASDAQ:IMVT) TODAYANNOUNCEDTHAT IT WILLREPORT ITSFINANCIAL RESULTS FOR THEFOURTHQUARTER AND FISCAL YEAR ENDEDMARCH31, 2026, AND PROVIDE A BUSINESS UPDATEAT 8:00 A.M.

IMMUNOVANTTOREPORT FINANCIAL RESULTS FOR THEFOURTHQUARTER AND FISCAL YEAR ENDEDMARCH31, 2026,AND PROVIDE BUSINESS UPDATEONWEDNESDAY,MAY20, 2026

LICHEN PLANOPILARIS (LPP) IS A HIGHLY MORBID INFLAMMATORY SCALP DISORDER THAT CAUSES GENERALLY IRREVERSIBLE SCARRING HAIR LOSS, OFTEN ACCOMPANIED BY PROFOUND PAIN, ITCH, AND BURNING SENSATIONS; NO FDA-APPROVED THERAPIES EXIST FOR LPP, HIGHLIGHTING A CRITICAL UNMET THERAPEUTIC NEED LPP MARKS THE FOURTH INDICATION IN BREPOCITINIB'S EXPANDING LATE-STAGE DEVELOPMENT PROGRAM MULTIPLE LINES OF EVIDENCE, INCLUDING STRONG MECHANISTIC RATIONALE AND CLINICALLY MEANINGFUL RESULTS IN AN INVESTIGATOR-INITIATED PLACEBO-CONTROLLED STUDY OF BREPOCITINIB IN LPP, SUPPORT RAPID DEVELOPMENT OF BREPOCITINIB IN THIS INDICATION A SEAMLESS PHASE 2B/3 POTENTIALLY REGISTRATIONAL TRIAL OF BREPOCITINIB IN LPP ENROLLED ITS FIRST SUBJECTS IN MARCH 2026 IMMUNOVANT'S PHASE 3 STUDIES OF BATOCLIMAB IN THYROID EYE DISEASE (TED) EACH FAILED TO MEET THEIR PRIMARY ENDPOINT; SAFETY RESULTS WERE CONSISTENT WITH PREVIOUS FINDINGS PATIENTS IN THE TED STUDIES DEMONSTRATED GREATER LEVELS OF PROPTOSIS IMPROVEMENT FROM BASELINE AFTER THE INITIAL 12-WEEK HIGH-DOSE PERIOD THAN AFTER THE FOLLOWING 12-WEEK LOW-DOSE PERIOD, SUPPORTING THE BENEFIT OF DEEPER IGG SUPPRESSION. THE HYPERTHYROID PATIENTS IN THE TED STUDIES SHOWED SIMILAR RESPONSE RATES OF THYROID HORMONE NORMALIZATION TO THOSE SEEN IN THE BATOCLIMAB PHASE 2 STUDY IN GRAVES' DISEASE IMMUNOVANT REMAINS FOCUSED ON RAPID ADVANCEMENT OF IMVT-1402 IN MULTIPLE INDICATIONS ROIVANT WILL HOST AN INVESTOR CALL TO DISCUSS THESE UPDATES TODAY, APRIL 2, 2026, AT 8:00 A.M.

ROIVANT ANNOUNCES EXPANSION OF BREPOCITINIB DEVELOPMENT PROGRAM WITH NEW PHASE 2B/3 TRIAL IN LICHEN PLANOPILARIS (LPP) AND PHASE 3 STUDY RESULTS FOR BATOCLIMAB IN THYROID EYE DISEASE (TED)

DURHAM, N.C., FEB. 06, 2026 (GLOBE NEWSWIRE) -- IMMUNOVANT (NASDAQ: IMVT), A CLINICAL-STAGE IMMUNOLOGY COMPANY DEDICATED TO ENABLING NORMAL LIVES FOR PEOPLE WITH AUTOIMMUNE DISEASES, TODAY REPORTED ITS FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED DECEMBER31, 2025.

IMMUNOVANT PROVIDES CORPORATE UPDATES AND REPORTS FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED DECEMBER31, 2025

DURHAM, N.C. AND NEW YORK, JAN. 23, 2026 (GLOBE NEWSWIRE) -- IMMUNOVANT (NASDAQ: IMVT) TODAY ANNOUNCED THAT IT WILL REPORT ITS FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED DECEMBER 31, 2025, AND PROVIDE A BUSINESS UPDATE AT 8:00 A.M. ET ON FRIDAY, FEBRUARY 6, 2026.

IMMUNOVANT TO REPORT FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED DECEMBER 31, 2025, AND PROVIDE BUSINESS UPDATE ON FRIDAY, FEBRUARY 6, 2026

NEW YORK, DEC. 11, 2025 (GLOBE NEWSWIRE) -- IMMUNOVANT, INC. (NASDAQ: IMVT), A CLINICAL-STAGE IMMUNOLOGY COMPANY DEDICATED TO ENABLING NORMAL LIVES FOR PEOPLE WITH AUTOIMMUNE DISEASES, TODAY ANNOUNCED THE PRICING OF AN UNDERWRITTEN OFFERING OF ITS COMMON STOCK, WITH ANTICIPATED GROSS PROCEEDS TO IMMUNOVANT OF APPROXIMATELY $550 MILLION, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OTHER EXPENSES PAYABLE BY IMMUNOVANT IN CONNECTION WITH THE TRANSACTION. ROIVANT SCIENCES LTD., THE COMPANY'S CONTROLLING STOCKHOLDER, HAS AGREED TO PURCHASE SHARES IN THE OFFERING. ALL OF THE SHARES ARE TO BE SOLD BY IMMUNOVANT.

IMMUNOVANT ANNOUNCES PRICING OF $550 MILLION COMMON STOCK FINANCING

STUDY IN UNCONTROLLED GRAVES' DISEASE (GD) PATIENTS TREATED FOR 24 WEEKS SHOWED FIRST-EVER POTENTIALLY DISEASE-MODIFYING OUTCOME WITH SIX-MONTH OFF-TREATMENT DATA IMVT-1402 DEVELOPMENT IS PROGRESSING WITH POTENTIALLY REGISTRATIONAL STUDIES IN GD, MYASTHENIA GRAVIS (MG), CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP), DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS (D2T RA) AND SJGREN'S DISEASE (SJD) REMAINS ON TRACK IMMUNOVANT REMAINS ON TRACK FOR THE FIRST OF THE TWO BATOCLIMAB PHASE 3 THYROID EYE DISEASE (TED) STUDIES TO READ OUT BEFORE THE END OF CALENDAR YEAR 2025. HOWEVER, DUE TO EVOLVING COMPETITIVE DYNAMICS, THE COMPANY ANTICIPATES SHARING TOPLINE RESULTS FROM BOTH TED STUDIES CONCURRENTLY IN THE FIRST HALF OF CALENDAR YEAR 2026 CURRENT CASH BALANCE PROVIDES RUNWAY FOR ANNOUNCED INDICATIONS THROUGH GD READOUT EXPECTED IN 2027 NEW YORK, NOV. 10, 2025 (GLOBE NEWSWIRE) -- IMMUNOVANT (NASDAQ: IMVT), A CLINICAL-STAGE IMMUNOLOGY COMPANY DEDICATED TO ENABLING NORMAL LIVES FOR PEOPLE WITH AUTOIMMUNE DISEASES, TODAY REPORTED ITS FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED SEPTEMBER 30, 2025.

IMMUNOVANT PROVIDES CORPORATE UPDATES AND REPORTS FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED SEPTEMBER 30, 2025

NEW YORK, OCT. 27, 2025 (GLOBE NEWSWIRE) -- IMMUNOVANT (NASDAQ: IMVT) TODAY ANNOUNCED THAT IT WILL REPORT ITS FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED SEPTEMBER 30, 2025, AND PROVIDE A BUSINESS UPDATE AT 8:00 A.M. ET ON MONDAY, NOVEMBER 10, 2025.

IMMUNOVANT TO REPORT FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED SEPTEMBER 30, 2025, AND PROVIDE BUSINESS UPDATE ON MONDAY, NOVEMBER 10, 2025

NEW YORK, SEPT. 03, 2025 (GLOBE NEWSWIRE) -- IMMUNOVANT, INC. (NASDAQ: IMVT), A CLINICAL-STAGE IMMUNOLOGY COMPANY DEDICATED TO ENABLING NORMAL LIVES FOR PEOPLE WITH AUTOIMMUNE DISEASES, TODAY SHARED AN ABSTRACT WITH SIX-MONTH OFF-TREATMENT DATA IN UNCONTROLLED GRAVES' DISEASE (GD) PATIENTS TREATED WITH BATOCLIMAB FOR 24 WEEKS, TO BE PRESENTED AT THE 2025 ANNUAL MEETING OF THE AMERICAN THYROID ASSOCIATION (ATA) ON SEPTEMBER 11, 2025.

ROIVANT UNVEILS DURABILITY AND TREATMENT-FREE SIX-MONTH REMISSION DATA WITH POTENTIAL TO CHANGE TREATMENT PARADIGM FOR UNCONTROLLED GRAVES' DISEASE PATIENTS

Immunovant, Inc.

IMVT

Price

Financial Reports

No items found.

Press Releases

Immunovant, Inc.

IMVT.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

IMVT